Argenx SE revenue

Argenx SE's revenue was $4.15bn in fiscal 2025, up 89.9% on the year before. Since fiscal 2015 ($7.6m) it has grown at a compound 87.8% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Argenx SE: revenue history, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	8	16	41	21	78	41	497	401	1,191	2,186	4,151
Growth on the year before	—	+114.2%	+152.6%	−47.8%	+265.2%	−47.4%	+>999%	−19.4%	+197.2%	+83.6%	+89.9%
Gross profit	—	—	—	—	—	—	—	371	1,073	1,959	3,701
Gross margin	—	—	—	—	—	—	—	92.7%	90.1%	89.6%	89.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Argenx SE	$4.15bn	89.9%	—
Neurocrine Biosciences Inc	$3.70bn	38.0%	27.5%
Biomarin Pharmaceutical Inc	$3.41bn	11.2%	15.1%
Biontech SE	$3.24bn	9.0%	—
United Therapeutics Corp	$3.15bn	2.5%	14.3%
Incyte	$6.01bn	24.9%	18.5%

Compare with peers

Head to head: ARGX vs NBIX ARGX vs BMRN ARGX vs BNTX ARGX vs INCY

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Argenx SE's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Argenx SE.